All news

Akebia Therapeutics cut to sell by Wall Street Zen

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Wall Street Zen downgraded Akebia Therapeutics (NASDAQ:AKBA) from hold to sell, even as the broader analyst consensus remains hold with an average price target of $3.90. The stock opened at $0.57, near its 12-month low, with negative net margin and return on equity despite a quarterly earnings beat. Investors face a split analyst view on a deeply discounted, unprofitable name.

Read original source

AKBA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.